<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zu D</submitter><funding>Natural Science Foundation of Zhejiang Province</funding><funding>Natural Science Foundation of China</funding><funding>National Natural Science Foundation of China</funding><funding>Zhejiang Medical and Health Science and Technology Program</funding><funding>Beijing Science and Technology Innovation Medical Development Foundation</funding><funding>Key Laboratory of Prevention, Diagnosis, and Therapy of Upper Gastrointestinal Cancer of Zhejiang Province</funding><pagination>e06294</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12667481</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12(44)</volume><pubmed_abstract>Radiotherapy is one of the most important adjuvant treatment methods for gastric cancer (GC). However, radioresistance remains a major clinical obstacle. In this study, APOL2 is identified as a key player in promoting non-homologous end joining (NHEJ)-mediated double-strand break (DSB) repair and enhancing radioresistance in GC. Bioinformatics and clinical data revealed that high APOL2 expression is correlated with poor prognosis in GC patients. Functional experiments showed that APOL2 overexpression enhances genomic stability by accelerating DSB repair via the NHEJ pathway, while APOL2 knockout impairs repair capacity. Mechanistically, APOL2 binds to and stabilizes Ku80 by enhancing USP7-mediated deubiquitylation, thereby increasing Ku80 protein levels to promote NHEJ repair, ultimately c</pubmed_abstract><journal>Advanced science (Weinheim, Baden-Wurttemberg, Germany)</journal><pubmed_title>APOL2 Stabilizes Ku80 to Confer NHEJ-Mediated Radioresistance in Gastric Cancer.</pubmed_title><pmcid>PMC12667481</pmcid><funding_grant_id>32370797</funding_grant_id><funding_grant_id>KC2023-JX-0270-07</funding_grant_id><funding_grant_id>82473195</funding_grant_id><funding_grant_id>LTGY23H160018</funding_grant_id><funding_grant_id>2024KY789</funding_grant_id><funding_grant_id>2022E10021</funding_grant_id><pubmed_authors>Liu H</pubmed_authors><pubmed_authors>Jing J</pubmed_authors><pubmed_authors>Hu Y</pubmed_authors><pubmed_authors>Liu M</pubmed_authors><pubmed_authors>He H</pubmed_authors><pubmed_authors>Guan F</pubmed_authors><pubmed_authors>Luo G</pubmed_authors><pubmed_authors>Du Y</pubmed_authors><pubmed_authors>Zhong Y</pubmed_authors><pubmed_authors>Deng M</pubmed_authors><pubmed_authors>Cheng X</pubmed_authors><pubmed_authors>Bao Q</pubmed_authors><pubmed_authors>Shi Y</pubmed_authors><pubmed_authors>Ye Z</pubmed_authors><pubmed_authors>Liang C</pubmed_authors><pubmed_authors>Li X</pubmed_authors><pubmed_authors>Huang Y</pubmed_authors><pubmed_authors>He Y</pubmed_authors><pubmed_authors>Zu D</pubmed_authors><pubmed_authors>Tainer JA</pubmed_authors><pubmed_authors>Xu S</pubmed_authors><pubmed_authors>Bacolla A</pubmed_authors><pubmed_authors>Zhang C</pubmed_authors><pubmed_authors>Wu W</pubmed_authors></additional><is_claimable>false</is_claimable><name>APOL2 Stabilizes Ku80 to Confer NHEJ-Mediated Radioresistance in Gastric Cancer.</name><description>Radiotherapy is one of the most important adjuvant treatment methods for gastric cancer (GC). However, radioresistance remains a major clinical obstacle. In this study, APOL2 is identified as a key player in promoting non-homologous end joining (NHEJ)-mediated double-strand break (DSB) repair and enhancing radioresistance in GC. Bioinformatics and clinical data revealed that high APOL2 expression is correlated with poor prognosis in GC patients. Functional experiments showed that APOL2 overexpression enhances genomic stability by accelerating DSB repair via the NHEJ pathway, while APOL2 knockout impairs repair capacity. Mechanistically, APOL2 binds to and stabilizes Ku80 by enhancing USP7-mediated deubiquitylation, thereby increasing Ku80 protein levels to promote NHEJ repair, ultimately c</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Nov</publication><modification>2026-06-05T20:43:42.388Z</modification><creation>2026-05-21T03:13:06.621Z</creation></dates><accession>S-EPMC12667481</accession><cross_references><pubmed>40953331</pubmed><doi>10.1002/advs.202506294</doi></cross_references></HashMap>